Back to Search Start Over

A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma

Authors :
Flinn, Ian W.
Ervin, Thomas J.
Boccia, Ralph V.
Flora, Douglas B.
Cuevas, J. Daniel
Thompson, Dana S.
Shipley, Dianna L.
Berdeja, Jesus G.
Source :
Blood; December 2015, Vol. 126 Issue: 23 p1492-1492, 1p
Publication Year :
2015

Abstract

Flinn: Celgene Corporation: Research Funding. Boccia:Incyte Corporation: Honoraria. Berdeja:Array: Research Funding; Curis: Research Funding; Onyx: Research Funding; Abbvie: Research Funding; Acetylon: Research Funding; Novartis: Research Funding; Celgene: Research Funding; Janssen: Research Funding; BMS: Research Funding; MEI: Research Funding; Takeda: Research Funding.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
126
Issue :
23
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs53082543
Full Text :
https://doi.org/10.1182/blood.V126.23.1492.1492